Guo H - Search Results

1

Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy.

Kong S, Zhang J, Wang L, Li W, Guo H, Weng Q, He Q, Lou H, Ding L, Yang B. Kong S, et al. Among authors: guo h. Cancer Lett. 2024 Dec 25;611:217432. doi: 10.1016/j.canlet.2024.217432. Online ahead of print. Cancer Lett. 2024. PMID: 39730087 Free article. Review.

2

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.

Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, Yang B, Ding L. Chen X, et al. Among authors: guo h. Acta Pharm Sin B. 2020 May;10(5):723-733. doi: 10.1016/j.apsb.2019.09.006. Epub 2019 Sep 25. Acta Pharm Sin B. 2020. PMID: 32528824 Free PMC article. Review.

3

Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.

Zhao L, Guo H, Chen X, Zhang W, He Q, Ding L, Yang B. Zhao L, et al. Among authors: guo h. Eur J Pharmacol. 2022 Jul 15;927:175071. doi: 10.1016/j.ejphar.2022.175071. Epub 2022 May 27. Eur J Pharmacol. 2022. PMID: 35636522 Review.

4

Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer.

Chen X, Du Q, Guo H, He Q, Yang B, Ding L. Chen X, et al. Among authors: guo h. Front Pharmacol. 2022 Jun 2;13:897747. doi: 10.3389/fphar.2022.897747. eCollection 2022. Front Pharmacol. 2022. PMID: 35721177 Free PMC article.

5

The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies.

Zhong T, Zhang W, Guo H, Pan X, Chen X, He Q, Yang B, Ding L. Zhong T, et al. Among authors: guo h. Acta Pharm Sin B. 2022 Apr;12(4):1761-1780. doi: 10.1016/j.apsb.2021.11.001. Epub 2021 Nov 5. Acta Pharm Sin B. 2022. PMID: 35847486 Free PMC article. Review.

6

The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy.

Zheng M, Zhang W, Chen X, Guo H, Wu H, Xu Y, He Q, Ding L, Yang B. Zheng M, et al. Among authors: guo h. Acta Pharm Sin B. 2023 Apr;13(4):1488-1497. doi: 10.1016/j.apsb.2022.10.027. Epub 2022 Nov 2. Acta Pharm Sin B. 2023. PMID: 37139414 Free PMC article. Review.

7

Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists.

Pan X, Zhang W, Guo H, Wang L, Wu H, Ding L, Yang B. Pan X, et al. Among authors: guo h. Biochem Pharmacol. 2023 Jul;213:115596. doi: 10.1016/j.bcp.2023.115596. Epub 2023 May 16. Biochem Pharmacol. 2023. PMID: 37201875 Review.

8

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA.

Zhang W, Pan X, Xu Y, Guo H, Zheng M, Chen X, Wu H, Luan F, He Q, Ding L, Yang B. Zhang W, et al. Among authors: guo h. Acta Pharm Sin B. 2023 Jun;13(6):2585-2600. doi: 10.1016/j.apsb.2023.04.002. Epub 2023 Apr 17. Acta Pharm Sin B. 2023. PMID: 37425040 Free PMC article.

9

KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer.

Pan X, Zhang W, Wang L, Guo H, Zheng M, Wu H, Weng Q, He Q, Ding L, Yang B. Pan X, et al. Among authors: guo h. Mol Oncol. 2023 Dec;17(12):2659-2674. doi: 10.1002/1878-0261.13512. Epub 2023 Sep 2. Mol Oncol. 2023. PMID: 37606530 Free PMC article.

10

Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies.

Wang L, Zhang W, Zhang J, Zheng M, Pan X, Guo H, Ding L. Wang L, et al. Among authors: guo h. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Sep 26;52(5):567-577. doi: 10.3724/zdxbyxb-2023-0263. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37916308 Free PMC article. Review. Chinese, English.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21,362 results

Search Page

Filters